Prostate Cancer Vaccine May Be Approved This Week

April 27, 2010


Naomi Haas, MD, as associate professor in the division of Hematology/Oncology and director of the Abramson Cancer Center's Prostate Program, is quoted in a CBS 3 story about the Food and Drug Administration's expected decision this week on a vaccine used to treat prostate cancer patients. The vaccine, which is made from a patient's own cells and a cancer-associated protein called prostatic acid phosphatase, is designed to spur the immune system to attack the cancerous tumor. Haas says that the therapeutic vaccine may offer patients a chance to be treated with fewer side effects than conventional options including surgery, radiation and chemotherapy. "Perhaps we'll make prostate cancer more of a chronic disease and less of a disease that's associated with side effects," she says... read more